Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › crenezumab

crenezumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of crenezumab

3 trials tracked of crenezumab.

3Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3
  1. Phase 2 A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab Completed
  2. Phase 2 A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort Completed
  3. Phase 2 Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds trivial cognitive effects of amyloid antibodies in mild Alzheimer's disease
Neurology Meta-analysis
Meta-analysis finds trivial cognitive effects of amyloid antibodies in mild Alzheimer's disease Alzheimer’s Drugs Clear Plaques But Don’t Help Memory
This meta-analysis of 17 randomized trials found amyloid-beta-targeting monoclonal antibodies probably have little to no effect on cognitive…
This review shows that even when Alzheimer’s drugs clear amyloid from the brain, patients don’t see meaningful improvements in memory or dai…
Apr 22, 2026